Novo had already become the highest valued in Denmark in 2008, overtaking container-shipping behemoth Moller-Maersk with the gap between the two firms widening ever since.

It’s now worth more than the combined value of all the other companies in the Danish benchmark index, helped by soaring sales of drugs to treat obesity and diabetes.

Josephine Cetti, Nordea Bank’s asset and wealth management division chief strategist said: “Novo has become a very dominant share in Denmark and the company also has a significant influence on the Danish business community. 

Novo has helped give Danish shares a stamp of quality as the company’s success is rubbing off on other companies in the eyes of investors.

Copenhagen’s stock exchange already changed its benchmark index in 2013 because Novo had grown too big and made up about 45% of the gauge. The index is now capped, meaning the weight of individual stocks can’t exceed 20%. If the old index was still used today, Novo would make up 58%.

“Having a successful company like Novo has probably also helped other Danish pharmaceutical companies get better access to funding,” Ms Cetti said, adding that acting as a talent pool has meant it has “helped raise the quality of Danish companies across the board”.

There us still some way to go for Novo to reach the dominant position that Nokia Oyj held for years in nearby Finland.

• Bloomberg